OptimizeRx vs Paysign
OPRX and PAYS side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OPRX and PAYS compare
Paysign is the larger company, worth 4.2 times as much as OptimizeRx ($554M against $131M).
On earnings, OptimizeRx is cheaper: it trades at 28.9× trailing earnings, against 37.7× for Paysign.
Paysign grew revenue faster over the last twelve months (46.8% versus −5.8% for OptimizeRx).
Paysign keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with 4.7% at OptimizeRx.
Paysign scores higher on the StockData Score (14 against 10 for OptimizeRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OPRX | PAYS |
|---|---|---|
| Size and price | ||
| Market cap | $131M | $554M |
| Share price | $6.94 | $9.81 |
| Change, 1 year | −54.3% | 92.0% |
| Change, 5 years | −89.9% | 401% |
| Beta (5Y) | 1.50 | −0.02 |
| Employees | 104 | 80 |
| StockData Score | ||
| Total score | 10 | 14 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 2 | 5 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 3 | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 28.9× (better) | 37.7× |
| P/S | 1.3× (better) | 5.5× |
| P/B | 1.0× (better) | 9.2× |
| EV/EBITDA | 8.3× (better) | 20.1× |
| P/FCF | 7.1× (better) | 7.5× |
| PEG | – | 0.44 |
| FCF yield | 14.0% (better) | 13.3% |
| Fair value | $9.96 | $9.74 |
| Margin of safety | 30.4% (better) | −0.70% |
| Growth | ||
| Revenue growth (TTM) | −5.8% | 46.8% (better) |
| Revenue growth, 5Y average | 20.4% | 27.7% (better) |
| Net income growth (TTM) | – | 133% |
| EPS growth (TTM) | – | 117% |
| Profitability | ||
| Gross margin | 73.2% (better) | 61.0% |
| Operating margin | 11.1% | 17.0% (better) |
| Net margin | 4.7% | 15.7% (better) |
| FCF margin | 18.6% | 73.0% (better) |
| Return on equity | 3.7% | 30.8% (better) |
| Return on invested capital | 5.8% | 35.2% (better) |
| Financial health | ||
| Debt / equity | 0.15 | 0.09 (better) |
| Net debt / EBITDA | −0.33 | −0.84 |
| Interest coverage | 2.3× | – |
| Current ratio | 5.58 (better) | 1.14 |
| Altman Z-score | 2.82 (better) | 2.04 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 59.6% | 53.6% |
| Held by insiders | 19.4% | 53.5% |
| Insider net buying, 12 months | −$18.8K (better) | −$8.4M |
| Short interest, % of float | 7.8% | 9.3% |
Go deeper
- OPRX stock overview
- OPRX income statement
- OPRX valuation and score
- PAYS stock overview
- PAYS income statement
- PAYS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.